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Candida species have increasingly deserved a special attention among the medical community. In spite of the presence of Candida
species as a human commensal, alarming rates of local and systemic infections have been observed, varying from moderate to
severe impact. Currently available antifungal drugs have progressively lost their effectiveness, pointing urgently the problem of
the microorganisms with acquired-resistance. Natural matrices are secularly used for numerous purposes, being inclusive and
highly effective as antimicrobials. Increasing evidence gives a particular emphasis to the contribution of phenolic extracts and
related individual compounds. In vitro studies clearly confirm their prominent effects, but the confirmation through in vivo studies,
including the involved mechanisms of action, is not so much deepened. Therefore, the present report aims to provide extensive
knowledge about all these aspects, highlighting themost efficient phytochemical formulations, including therapeutic doses. Further
studies need to be incited to deepen knowledge on this area, namely, focused on clinical trials to provide safer and more effective
antimicrobials than the current ones.
1. Introduction
Over the last years, plant-derived extracts and related phy-
tochemicals have gained a particular attention by scientific
researchers, due to their healing effects [1–3]. Studies involv-
ing the elucidation of their mechanisms of action, including
pharmacokinetics and pharmacodynamics, have been also
performed [4–8]. In the last two decades, among its phy-
totherapeutic properties, the antimicrobial potential, namely,
anti-Candida effects, has deserved a particular attention. In
fact, Candida species have been implicated in an onset of
mild and severe clinical conditions, although it was con-
sidered a commensal microorganism of healthy individuals
[9].
In themajority of cases, patients have no infection signals
and symptoms manifestation; thus, upon a clinical diagnosis,
a severe colonization and related infection are installed
[9]. Antifungals and even other antimicrobial drugs are,
therefore, extensively prescribed; but the present condition
is much more complex than simple Candida species over-
growth [9]. Other triggering factors are also involved, which
are neither considered nor regulated by the antimicrobials.
Obviously, recurrent infections will be installed, leading
to the appearance of microorganisms highly resistant to
conventional antifungal drugs [10–12].
Plants and all living organisms produce countless sub-
stances aiming at their survival, defence, nutrition, and
even growth [13–15]. Regarding their antimicrobial proper-
ties, namely, antifungals, some of them have already been
described. Phenolic compounds, namely, phenols, flavonoids,
coumarins, quinones, saponins, and xanthones, are the
most abundant, besides alkaloids, lectins, polypeptides,
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terpenoids, and essential oils [15–18]. In vitro studies are
crucial to screen their effects [19], security, efficiency, and
other biochemical parameters, but plant-derived bioactive
molecules possess several modes of action, establishing
synergic, antagonist, and polyvalent relationships with other
compounds, besides suffering chemical changes due to
organic metabolism, including the effects on gut microbiota
[5, 20, 21]. Those features could not be assessed through in
vitro and, therefore, in vivo studies, and mostly clinical trials
shall be also considered.
In this sense, the present report intends to provide
extensive knowledge on in vivo anti-Candida potential of
phenolic extracts and compounds. Furthermore, the in vivo
mechanisms of action of the previous will be presented, as
well as potential clinical applications (i.e., galenical formula-
tions, among others).
2. Candida Species: Clinical Impact
2.1. Epidemiological Features. Microorganisms are ubiqui-
tous and, in adequate concentrations, are crucial to the
organic homeostasis. To ensure this equilibrium, friendly
microbiota, gastrointestinal pH, immune system, and organic
metabolism play a role of the utmost importance [22,
23]. Nevertheless, daily routine, environmental factors, and
people lifestyles, among other factors, act as triggers to
unbalance. Additionally, higher levels of stress, the overuse
of antibiotics, antacids and proton-pump inhibitors, birth
control pills or steroids, the exposure to environmental chem-
icals, and wrong food choices (namely, diets with too many
sugars, alcohol, and fermented products) are encountered
between the most common causes of dysbiosis. Much more
than a “dys” (which means not) and “symbiosis” (which
means living together in mutual harmony), dysbiosis reflects
the relationship between microbes and the host [22, 23].
In contrast with some high-virulence microorganisms that
cause immediate reactions, low-virulence microorganisms
are insidious. Candida species, considered a commensal
microorganism, comprises an excellent example [22–24].
Among them,C. albicans is encountered as themost frequent,
being responsible for approximately 50–90% of cases of
human infection (candidiasis) [9]. But presently, other non-
albicans Candida species have also been involved, mainly
C. tropicalis, C. glabrata, C. dubliniensis, and C. parapsilosis.
Besides their associated virulence features, they are also able
to form biofilms with other species, which not only makes
their eradication difficult but also improves their prevalence
and related resistance to antimicrobials [9, 25]. Thus, and
despite providing several benefits to the host, they possess
a higher adaptability and numerous strategies to survive,
which not only favors their overgrowth but also changes
their susceptibility profiles.The human organism is colonized
by these yeast species at, or near, birth, mainly through a
physical contact with the vaginal flora [25–27]. Under normal
physiological conditions, Candida species are present in
small amounts, but some individual characteristics determine
the probability of Candida overgrowth and, consequently,
establishment of infection. For example, women are most
susceptible, as hormonal variations act as triggering factors,
but men could also be affected [9, 28].
Previous to the synthesis of chemical drugs, namely,
antibiotics and other antimicrobials, microorganisms nat-
urally produce natural biocides towards each other, but
also establishing symbiotic relationships [22, 29, 30]. Nev-
ertheless, due to the disseminated adhesion to the use and
overuse of antibiotics, not only in humans but also in
animals, numerous microorganisms with undergoing muta-
tions have appeared, and linked with this, the rates of
chronic and degenerative problems soared in an exponential
manner.
2.2. Drug Resistance. A large amount of antimicrobial drugs,
such as antibiotics and antifungal agents, is currently available
to fight against a wide variety of infectious syndromes [31, 32].
Once these drugs act in a nonspecific way, they kill not only
harmful but also helpful microorganisms, including healthy
microbiota, apart from interfering with several metabolic
pathways [22, 29, 30]. As previously mentioned, oppor-
tunistic microorganisms may be present in small amounts
in healthy organisms, without causing any clinical distur-
bance or infectious symptoms. But, unfortunately, in the last
decades, in the face of a minimal symptom of infection,
antimicrobial drugs are widely prescribed, mostly without
determining the causative agent. The fact that unbalanced
diets and nutrient deficiencies are important secondary
causes of infection is completely ignored [22, 30]. In fact,
several nutrients are crucial to maintain a healthy immune
system [22, 23, 32]. So, it is easy to understand that, in the
face of nutritional deficits, the defense system cannot work
properly, and so the probability of occurrence of oppor-
tunistic infections and other organic disorders is significantly
improved.
In the face of the higher rates of microorganisms with
acquired drug resistance, among which are Candida species-
related infections, scientific advances regarding new synthetic
drugs, more specific and effective than the previous, have
been supported by pharmaceutical industries. The current
ones are ineffective not only at higher doses but also in drug
combination [10, 33–35].Themost prominent situation is the
acquired-resistance to azoles, mainly by enhancement of its
efflux through upregulation of multidrug transporter genes
on yeast cells, besides changes in the ergosterol biosynthesis
and occurrence of mutations. The new synthetic drugs seem
to be effective against themajority of insidious- and resistant-
Candida species [35–40], but the problem of their side effects
and related toxicity still remains.
2.3. Upcoming Approaches. Plants comprise an extremely
rich pool of bioactive constituents [41–45]; most of them
are secondary metabolites (final or intermediate products)
[14, 45–47]. Among them, phenolic compounds have gained
a special attention in the last years. In fact, numerous studies
have pointed their prominent antifungal potential [16, 45, 46,
48–50].
The use of botanical preparations is an ancient practice,
but without a solid scientific basis, it is poorly accepted
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by the medical community. Numerous underlying inter-
ests have blocked its worldwide recognition, in spite of
its evident effectiveness and absence of side effects and
toxicity, when properly used. It is a fact that several studies
have reported problematic herbal-drug interactions [51–53],
but it is very important to highlight that the majority of
synthetic chemicals are derived from plants, that they act
on symptoms and not in the predisposing cause(s), that
they only possess one or another therapeutic indication, and
that the magnitude of side effects and toxicity is directly
related with the prescribed dosages [22, 32]. On the other
hand, natural matrices, besides providing a wide variety of
phytotherapeutic properties, improve and even contribute
to a proper nutritional balance [22–24, 54]. Furthermore,
these bioactive molecules show a higher spectrum of clinical
applications, due to the occurrence of synergic, antagonistic,
and polyvalence reactions; their side effects and related
toxicity disappeared and/or are neutralized, as well as being
able to favor the organic homeostasis, providing not only
immunomodulatory and healing properties, but also other
health benefits [22, 23, 55].Thus, while botanical preparations
act in a holistic manner, the chemical drugs mainly block
one or more metabolic pathways improving the organic
unbalance [22–24, 32]. Among the intensive research on
this area, in vitro studies clearly assume the leadership,
while in vivo studies remain secondary. Notwithstanding, in
vitro studies have clear limitations, Notwithstanding, in vitro
studies have clear limitations; so, apart from the discovery of
potentially effective alternatives, is also important to analyze
its feasibility and to access the involved modes of action,
through in vivo studies.
3. Clinical Importance of In Vivo Studies
3.1. Historical Perspective. The diagnosis of an infection
comprises several levels of complexity, and currently the
idea that the presence of some microorganisms is inoffensive
was changed completely [56, 57]. In particular, opportunis-
tic microorganisms, including Candida species, can cause
from a simple catheter-related fungemia or peritonitis to
severe localized infections, or even extensive hematogenous
dissemination [9, 57, 58]. Immunocompromised patients,
transplanted or submitted to broad surgeries, individuals
with neoplastic diseases, and children and elderly people are
considered as a higher risk population, beingmuchmore vul-
nerable than other common citizens [9, 58]. In this sense, and
considering that in some cases neither signals nor symptoms
are observed, it is crucial to establish a correct diagnosis,
which implies not only the use of representative isolated
clinical material, but also the isolation and identification
of the involved microorganism, towards a correct clinical
intervention [56, 57].
In the first stages of the clinical investigation, in vitro
techniques (such as microscopic, serologic, antigenic, ampli-
fication, and susceptibility tests) are extremely useful, but it
is necessary to highlight that they do not consider numerous
variables, namely, the individual idiosyncrasies and organic
metabolism. Thus, and regarding the latest advances related
with the opportunistic fungal infections, numerous in vitro
studies have been carried out, including the screening of
some natural extracts (e.g., rich in phenolic compounds)
with anti-Candida potential [19], but also evaluating their
mechanisms of actions and other laboratorial parameters
(i.e., proteomic, genetic, molecular studies, etc.) [5, 6, 50, 59,
60]. Notwithstanding, in vivo studies still remain scarce.
3.2. In Vivo Antifungal Potential of Phenolic Extracts. Table 1
shows the phenolic extracts with reported in vivo activity
against Candida species. Combretaceae followed by Acan-
thaceae are the most studied plant families. Considering
the obtained results, leaves, followed by the seeds and
fruits, and then flowers appear as the most enriched-plant
parts. In fact, leaves and seeds/fruits show higher levels
of phenolic compounds, but their concentrations depend
greatly on the growth, harvesting, and storage conditions [61–
64]. Additionally, the extractability of phenolic compounds
depends on the type of solvent used [19]. Methanol, fol-
lowed by acetone, water, ethanol, petroleum ether, methanol-
dichloromethane, ethyl acetate, and n-butanol encounter
between themost frequently used extraction solvents. In fact,
these solvents were also the most commonly used in the in
vitro studies dealing with anti-Candida potential of phenolic
extracts [19].
The neutrophils adhesion, locomotion, and chemotaxis
tests, as well as the assessment of their phagocytic activity
to kill C. albicans, have been some of the parameters used
to evaluate the activity of phenolic extracts against Candida
species [65, 66]. The obtained results allow not only the
determination of the abundance of neutrophils in blood
samples, in terms of number of total leukocyte cells (TLC)
and differential leukocyte cells (DLC), but also the analysis of
the efficiency/capacity to kill C. albicans. Haemagglutinating
antibody (HA) titre and delayed-type hypersensitivity (DTH)
response tests have been also carried out [67]. The obtained
results from these tests can be considered direct indicators
of the status of the immune system and also allow the
determination of the immunomodulatory potential of the
studied substances. The humoral immune response presup-
poses the existence of phagocytic activity but also includes
other immune-related organic reactions, such as induction of
synthesis, reproduction, and differentiation of defense cells.
In this sense, the previous assays give specific information
relatedwith the activity and efficiency of organic-defense cells
to ingest, to remove, and to destroy not onlymicroorganisms,
but also malignant cells, inorganic particles, and altered
tissues.
Evaluation of the wound healing potential, for example,
through measuring the tensile strength, exudate, lesion size,
crust formation, and also histological and histopathological
examinations, has been applied by some authors [68–75].
In fact, the colonization of wounds by microorganisms
is very common; thus, it is extremely useful to discover
plant extracts with pronounced abilities to improve, for
example, wound closure and crust formation. Among the
wide variety of plant’s secondary metabolites, flavonoids, but
specifically tannins, havemarked astringent, antioxidant, and
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also antimicrobial potential and, therefore, a direct influence
in wound contraction and healing potential [69, 73].
The evaluation of the efficiency/efficacy of plant extracts
in induced systemic and local infection models is a very
interesting approach, once it mimics the real conditions of
infected organisms and, at the same time, the achievement
of the direct effect of the tested substances. Vijayarathna et
al. [76], Jothy et al. [77], Sahgal et al. [75], and Dzoyem et
al. [78] evaluated the effects of plant extracts in systemic
infections, while Arau´jo et al. [70] and Simonetti et al. [79]
in induced vaginal infection, Abaineh and Sintayehu [80] in
local mastitis, and, lastly, Chelli-Chentouf et al. [81] in oral
health and improvement decays in children.
Although the aim of the present report is to highlight
the in vivo anti-Candida potential of phenolic extracts and
compounds, it should be noticed that natural matrices pos-
sess much more than a single bioactivity and that the sum of
several bioactivities might result in a different final clinical
application. Furthermore, a unique bioactive potential (con-
ferred by a specific or several chemical compounds) is able
to improve considerably other bioactive effects. For example,
several reports have shown that plant extracts with a signif-
icant antioxidant potential also evidence considerable anti-
inflammatory and antimicrobial effects [42, 82–85]. Besides,
plant extracts with higher antifungal potential normally exert
significant immunomodulatory and also antiseptic effects.
Thus, and in the same line with the results of several authors,
plant extracts that present a considerable healing potential
have also a great antioxidant, antiseptic, and antimicrobial
activities. Phenolic compounds are the most representative
chemical compounds with the above-described bioactive
properties, but due to the slight number of in vivo studies
reporting their anti-Candida potential, few conclusions can
be stated. Beyond that, C. albicans is the main focus of
the present studies, but other non-albicans Candida species
should be also considered once present in different infections.
3.3. In Vivo Antifungal Potential of Individual Phenolic
Compounds. Table 2 shows the in vivo antifungal potential
of phenolic compounds against Candida species. Stilbenes,
namely, pterostilbenes and riccardin D, are the most studied
phenolic compounds with anti-Candida potential, followed
by curcuminoids (curcumin and piperine). Its respective
chemical structures are shown in Figure 1. Among the tested
stilbenes, pterostilbenes evidenced a higher anti-Candida
biofilm activity than the riccardin. Li et al. [86] observed
a total inhibition of the biofilm formation by using con-
centrations of 32 𝜇g/mL and 64 𝜇g/mL of pterostilbenes;
at 16 𝜇g/mL, C. albicans biofilms were defective and only
sparse cells were founded. In contrast, the same authors [87],
evaluating the effect of riccardin D on anti-Candida biofilm
formation, did not observe a complete growth inhibition by
using a concentration of 64𝜇g/mL.
Concerning the evaluation of the antifungal potential of
curcuminoids, Sharma et al. [88] showed that the use of
curcumin alone provides an insignificant effect, due to its
poor bioavailability, but when administered in association
with piperine, an inhibitor of the hepatic and intestinal
glucuronidation, its efficacy, and related antifungal efficiency
was completely changed. For example, the antifungal poten-
tial of associated substances, curcumin (100mg/kg) in combi-
nation with piperine (20mg/kg), presents a similar potential
to the current antifungal drug fluconazole (50mg/kg).
Nevertheless, considering the scarce number of studied
phenolic compounds, no solid conclusions can be proposed.
Additionally, commercial standards are encountered as the
most studied, alternative to the plant-derived phenolic com-
pounds. Candida albicans continues to be the most focused
Candida species, but concerning the real clinical condi-
tions, for example, catheter infections and systemic infection
models, other non-albicans Candida species should be also
considered. Rats, particularly albino and immunocompro-
mised, have been the mostly used animal models due to not
only their higher susceptibility to infections, but also weak
efficiency of their immune system andpolymedication.Per se,
the multidrug administration is an isolated triggering factor
that gives higher vulnerability to organisms. In the same line,
several classes, ways of administration, and infection models
should be also studied, by inducing oral cavity, bloodstream,
and vaginal, ocular, nails, and skin infections, once they
are the most commonly effected tissues by these yeasts.
Furthermore, the prophylactic effect of plant extracts (e.g.,
phenolic extracts) and related individual compounds should
be also considered. In fact, the prevention of fungal infections
might be as important as the therapeutic intervention.
Considering all the above described features, more
detailed studies should be carried out, aiming not only at a
better comprehension of the present problematic conditions,
but also at providing new and more effective alternative
treatments (including a prophylactic approach) and, lastly,
at giving consistent data and specific tools towards a future
approach regarding clinical trials.
4. Anti-Candida Species Inherent
Mechanisms of Action
Although several studies have been carried out evaluating
the antifungal mechanisms of action of natural matrices and
isolated compounds, the experimental studies involving phe-
nolic matrices with evidenced in vivo anti-Candida potential
are considerably scarce. Among the in vitro determined
anti-Candida potential of natural matrices, the effects on
the immune system, namely, macrophage activation and
upregulation of the expression of receptors related with
phagocytosis, were one of the most accessed mechanisms
[65].Martino et al. (2011) concluded that the studied fractions
of the aqueous extract of Larrea divaricata Cav. improve
the superoxide anion production and, consequently, increase
the phagocytosis of C. albicans and improved the nitric
oxide (NO) production when compared with controls.Those
fractions evidenced not only a direct action on macrophage
activation, but also an indirect effect on production and
releasing of ROS and NO, which enhanced the destruction
of the invaders. On the other hand, Roy et al. [74], evaluating
the antimicrobial and wound healing potential of Pyrostegia
venusta Miers, proposed that the evidenced healing effects
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Figure 1: Chemical structures of the tested bioactive molecules with in vivo anti-Candida potential.
were related with the accumulation of the anti-inflammatory
and proinflammatory cytokines and cells of immune system,
particularly monocytes and macrophages, as also due to
the antimicrobial effects of the tested natural matrix in the
local of the tissue injury. In addition, Chen et al. [69],
evaluating the wound healing and anti-inflammatory poten-
tial of Lonicera japonica Thunb. and related mechanism of
wound contraction, concluded that these effects were mainly
attributed to the improvement of collagen and granulation
tissue formation, fibroblast proliferation, angiogenesis, and
consequently stimulation of the reepithelialization. Further-
more, the authors proposed that these effects were also due
to the existence of synergistic effects between antimicrobial
and anti-inflammatory properties of the active ingredients,
including chlorogenic acid.
Kumar et al. [67] evaluating the immunomodulatory
potential of Phyllostachys bambusoides Siebold & Zucc, con-
cluded that the observed effects were mainly due to the
upregulation of themacrophage activation and, consequently,
induction of the phagocytic activity. The observed effects
were in part derived from the improvement of NO pro-
duction. These facts resulted in a significant increase of
the macrophage phagocytic activity of Candida species as
well as in a promotion of the proliferation, maturation,
and improvement of the immunological function of other
immune defense cell types, resulting in an effective eradica-
tion of the invaders.
Otherwise, the effects of the phenolic extracts could be
exerted directly in Candida species, instead of in the host
individuals. Figure 2 shows the most common sites of action
of the antifungal drugs. The interaction with the fungal
membrane and its specific components has been described
as one of the most common targets of natural matrices.
Cellular 
membrane
Nucleus
Cellular
 wall
Mitochondria
Golgi apparatus
Endoplasmic reticulum 
(rough and smooth)
Figure 2: Mechanisms of action of the in vivo tested phenolic
extracts and compounds against Candida species.
Associated with an increasing number of resistant-Candida
species to the conventional antifungal agents, and reminding
the predominance of critical infections, the discovery of new
and effective alternatives is of the utmost relevance. It is
a fact that several antifungal agents, such as azoles (e.g.,
fluconazole) and others that interact with fungal membrane,
mainly exert fungistatic effects, despite their current higher
rates of inefficiency. Among the reports about the anti-
Candida activity of plant extracts, the associated modes of
action of those plant extracts and even isolated compounds
have been increasingly clear. For example, Jothy et al. [77]
described a higher anti-Candida activity of the methanol
extract of Cassia fistula Linn. seeds and carried out an
evaluation of the mechanisms of action, by scanning electron
microscope (SEM) and transmission electron microscope
(TEM) observations.The authors verified that, in comparison
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with controls, treated cells presented a significant small
size, irregular shape, with cell wall modifications, and clear
depressions on the cell surface with holes. Furthermore, and
after 12 h, the leakage of ions between treated and untreated
cells appears to be the same; between 12 and 36 h, a significant
increase in K+, Ca2+, and Mg2+ leakage has occurred in the
treated cells. It means that, during the first 12 h, the applied
extract exerts a little effect on the cell membranes but, after
this time, its disruption associated with an important surface
alteration and related damage were observed. As proposed by
the authors, the anti-Candida activity of C. fistulamay occur
by two main modes: firstly, a passive entrance of the seeds
extract into the plasma membrane, initiating the membrane
disruption and, then, by the accumulation of the C. fistula
seeds extract in the plasma membrane that results in cell
growth inhibition.
Concerning to the mechanisms of action of isolated
phenolic compounds, Li et al. [86], evaluating the activity of
pterostilbene (PTE), a stilbene-derived phytoalexin, against
C. albicans biofilms formation, observed a dose-dependent
antibiofilm effect from the PTE concentration used. These
achievements were mainly due to the disruption potential,
induction of filamentous defects, and reduction of the cell
density. In addition, the authors assessed the effect of PTE
on gene expression and observed that, at 16𝜇g/mL, 307
genes were differentially expressed: 193 were downregulated
and 114 were upregulated. The observed downregulated
genes were mainly related with the process of ergosterol
biosynthesis, function of oxidoreductase activity, and com-
ponents of the cell surface, while the upregulated genes were
related with the process of protein unfolding (heat shock
proteins). RAS1 (the RAS signal transduction GTPase gene),
ECE1 (cell elongation protein gene), SAP5 (secreted aspartyl
proteinase gene), SAM2 (S-adenosylmethionine synthetase
gene), PGA10 (involved in cell surface), and ERG11 (involved
in the ergosterol biosynthesis) are some of the downregulated
genes. On the other hand, ESC4 (related with the inhibi-
tion of biofilm formation), YWP1 (encoding yeast cell wall
protein), CEK1 and RIM8 (involved in filamentation), and
HSP78 (involved in protein unfolding) were found among
the upregulated genes. Furthermore, the authors described
that the PTE also exerts an effect on the Ras/cAMP pathway,
once after the PTE treatment and the exogenous cAMP
restored the yeast-to-hypha morphological transition, and
they also concluded that PTE was able not only to inhibit
the biofilm formation but also to destroy the maintenance of
mature biofilms. Lastly, by studying the in vivo antibiofilm
potential of PTE, the authors confirmed all of the above
proposed theories and also observed that PTE presents
a high bioavailability and no toxicity on the tested mice
models [86].
In the same line, Sharma et al. [88], studying the in vivo
antifungal potential of curcumin and its mode of action,
concluded that curcumin acts by mediating the ROS signal-
ing pathway and, consequently, stimulates the proapoptotic
regulatory processes by increasing the number of preapop-
totic cells. Notwithstanding, the authors also described
that the addition of an antioxidant could prevent these
effects. Furthermore, it was showed that curcuminmodulated
the drug efflux of yeast ABC transporters without affecting
the levels of transcription genes encoding these transporters.
A block of the hyphae growth was also reported by the
authors, not only in C. albicans but also in other non-albicans
Candida species, and in this case, the addition of antioxidants
could not reverse the inhibitory effect. Lastly, the authors
verified that curcumin targeted the global repressor TUP1
(thymidine uptake 1) which, in an independent manner of
ROS production, prevented the hyphae development, in both
liquid and solid hypha-inducing media [88].
Taking into account the above-described mechanisms
of action of phenolic extracts and related individual com-
pounds, it is feasible to conceive that plant extracts could be
promisor antifungal agents. Moreover, no toxicity was found
to the majority of the tested phenolic matrices, which itself
opens new perspectives for the future approach as new anti-
Candida leaders.
5. Current Phytochemical Formulations
Several phytochemical preparations are currently available,
for either external or internal uses [89]. Creams, lotions,
powders, sprays, and ointments are mainly directed for
cutaneous mycosis and onychomycosis, while suspensions,
capsules, drops, or suppositories have been used for mucous
infections.
Table 3 shows the most frequent in vivo phytochemical
preparations for intraperitoneal, intravaginal, intravenous,
oral, and topical uses. Oral administration, followed by
topical, intraperitoneal, intravaginal, and intravenous admin-
istrations, is one of the most common administration
ways. For oral administration, several types of suspen-
sions, aqueous solutions, direct-plant extract application,
and mouthwashes were also tested. In relation to mouth-
washes, toothbrushes with toothpaste and interdental clean-
ers are, currently, the most common procedures in order
to maintain a correct oral hygiene. However, and despite
some mouthwashes and mouthrinses being also available,
alcohol is commonly used in order to ensure a correct
dissolution of the active ingredients. Its use has been ques-
tioned because the alcohol-containing mouthwashes induce
desiccation of the oral mucosal membranes. Thus, it is
very important to prevent, reduce, and even treat plaque
microbial-associated diseases but also to ensure that the
used preparations are naturally safe and efficient. In this
sense, a mouthwash solution was applied by Chelli-Chentouf
et al. [81] in a children’s school, in order to evaluate not
only its efficiency but also its stability and physicochemical
parameters.
Creams and ointments are the most studied formulations
for topical use in fungal infections, mainly in cases of local
affections, such as excision and incision wounds, and vaginal
infectionmodels. In the last case, intravaginal administration
is the highly indicated, as also cream, solution, or even sus-
pension [70, 79]. Nevertheless, other phytochemical prepa-
rations have also been administered in laboratorial models,
namely, by intraperitoneal [65, 75, 77] and intravenous [78]
ways.
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Table 3: Phytochemical preparations evaluated through in vivo laboratorial models.
Application In vivomodel Type of formulation Reference
Intraperitoneal
Immunomodulation Solution (water) [65]
Intravenous Candida
infection
Solution (methanol) [77]
Suspension (methanol) [75]
Intravaginal Vaginal infection Cream (o/w emulsion) [70]
Suspension [79]
Intravenous Intravenous Candida infection Solution (water) [78]
Orally
Anti-inflammation,
antinociceptive and would
healing potential
(incision/excision models)
Suspension (0.5% sodium carboxy methyl cellulose (CMC)) [72]
Excision and incision wound Suspension (extract in vehicle) [74]
Immunomodulation Suspension (1% sodium carboxy methyl cellulose (CMC)) [66]
Suspension (1% w/v aqueous gum acacia) [67]
Intravenous Candida infection Solution (aqueous) [76]
Oral cavity children affections Mouthwash (water) [81]
Subclinical mastitis Crude extracts (cooked and powder leaves) [80]
Topically
Excision and incision
wound
Ointment (vehicle) [72]
Cream (aqueous) [71]
Excision wound
Cream (aqueous) [73]
Ointment (w/w) [69]
Ointment (w/w) [90]
Ointment (vehicle) [68]
It is convenient to highlight that the laboratorial formu-
lations are specifically designed according to the examined
clinical models; that is, for local/topical uses, creams, oint-
ments, and also intravaginal administration comprise the first
choice to evaluate the wound healing and antifungal potential
in externally affected models, while suspensions, solutions,
and mouthwashes are specifically indicated for internal
uses (oral, intraperitoneal, and intravenous) in laboratorial
models, such as in cases of induced systemic infections,
immunomodulation, anti-inflammatory, and antinocicep-
tive, and in some cases healing potential. In addition, in some
phytochemical preparations, histological and histopatholog-
ical studies were also carried out [68–75]. The evaluation
of the tissues architecture between controls, pretreated and
treated models, is of extreme relevance. The obtained results
by these studies allow an effective determination of the toxic
potential but also predict its possible types/ways of use,
providing upcoming information related with its possible
clinical applications.
6. Conclusion and Future Perspectives
Microorganisms are able to provide several benefits to
the host (due to the establishment of symbiotic relation-
ships) but are also responsible for severe health conditions.
Antimicrobial agents are normally effective, but due to their
overuse and related side effects and toxicity, its effective-
ness has been seriously questioned. Plants phenolic extracts
and isolated compounds possess a multitude of healing
properties. Methanol, followed by acetone, water, ethanol,
petroleum ether, methanol-dichloromethane, ethyl acetate,
and n-butanol extracts obtained from leaves, seeds, fruits,
and flowers comprise extremely enriched-phenolic sources.
Despite the pool of phenolic compounds present in phyto-
chemical preparations, only stilbenes (namely, pterostilbenes
and riccardin D) and curcuminoids (curcumin and piperine)
have been studied for their in vivo anti-Candida effects.
Oral (suspension, solution, mouthwash, and crude extracts),
followed by topical (ointment and cream), intraperitoneal
(solution and suspension), intravaginal (cream, solution,
and suspension), and intravenous (solution), phytochemical
formulations were often prepared for in vivo administra-
tion.
In fact, phytochemicals are the basis for the design and
development of new synthetic drugs, but while synthetic
chemical drugs act by a single way, natural matrices are able
to establish synergisms, antagonisms, and even polyvalence
effects. In vitro studies are normally the first choice to evaluate
the healing properties of natural matrices. However, in vivo
studies present a higher importance, Once considers the
organic metabolism and pharmacokinetic and pharmacody-
namic parameters, among other factors.
Overall, and apart from the stated advances, upcoming
specific clinical formulations, ways of administration, and
therapeutic dosage need to be established, being clinical trials
very important to deepen knowledge through more detailed
in vivo studies.
12 BioMed Research International
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
The authors are grateful to Foundation for Science
and Technology (FCT, Portugal) for N. Martins Grant
(SFRH/BD/87658/2012), L. Barros researcher contract
under “Programa Compromisso com Cieˆncia-2008,” and
financial support to the research centre CIMO (strategic
project PEst-OE/AGR/UI0690/2014). This work was also
supported by the Programa Operacional, Fatores de
competitividade-COMPETE and by national funds through
FCT (Fundac¸a˜o para a Cieˆncia e a Tecnologia) on the
scope of the Projects FCT PTDC/SAU-MIC/119069/2010,
RECI/EBB-EBI/0179/2012, and PEst-OE/EQB/LA0023/2013.
The authors thank the Project “BioHealth-Biotechnology
and Bioengineering approaches to improve health quality,”
Ref. NORTE-07-0124-FEDER-000027, cofunded by the
Programa Operacional Regional do Norte (ON.2-O Novo
Norte), QREN, and FEDER.
References
[1] E. A. Palombo, “Traditional medicinal plant extracts and
natural products with activity against oral bacteria: potential
application in the prevention and treatment of oral diseases,”
Evidence-Based Complementary and Alternative Medicine, vol.
2011, Article ID 680354, 15 pages, 2011.
[2] A. Sher, “Antimicrobial activity of natural products frommedic-
inal plants,” Gomal Journal of Medical Sciences, vol. 7, no. 1, pp.
72–78, 2009.
[3] L. Rubio´, M.-J. Motilva, and M.-P. Romero, “Recent advances
in biologically active compounds in herbs and spices: a review
of the most effective antioxidant and anti-inflammatory active
principles,” Critical Reviews in Food Science and Nutrition, vol.
53, no. 9, pp. 943–953, 2013.
[4] O. A. Ogundare, “The antimicrobial pattern and phytochemical
properties of the leaf extracts of Senna podocarpa,” African
Journal ofMicrobiologyResearch, vol. 3, no. 7, pp. 400–406, 2009.
[5] D. S. Alviano and C. S. Alviano, “Plant extracts: search for new
alternatives to treatmicrobial diseases,”Current Pharmaceutical
Biotechnology, vol. 10, no. 1, pp. 106–121, 2009.
[6] G. Lopes, E. Pinto, P. B. Andrade, and P. Valenta˜o, “Antifungal
activity of phlorotannins against dermatophytes and yeasts:
approaches to the mechanism of action and influence on
Candida albicans virulence factor,” PLoS ONE, vol. 8, no. 8,
Article ID e72203, 2013.
[7] B. B. Mishra and V. K. Tiwari, “Natural products: an evolving
role in future drug discovery,” European Journal of Medicinal
Chemistry, vol. 46, no. 10, pp. 4769–4807, 2011.
[8] M. N. Asl and H. Hosseinzadeh, “Review of pharmacological
effects of Glycyrrhiza sp. and its bioactive compounds,” Phy-
totherapy Research, vol. 22, no. 6, pp. 709–724, 2008.
[9] N. Martins, I. C. F. R. Ferreira, L. Barros, S. Silva, and
M. Henriques, “Candidiasis: predisposing factors, prevention,
diagnosis and alternative treatment,” Mycopathologia, vol. 177,
no. 5-6, pp. 223–240, 2014.
[10] T. C. White, K. A. Marr, and R. A. Bowden, “Clinical, cellular,
and molecular factors that contribute to antifungal drug resis-
tance,” Clinical Microbiology Reviews, vol. 11, no. 2, pp. 382–402,
1998.
[11] D. S. Perlin, “Resistance to echinocandin-class antifungal
drugs,”Drug Resistance Updates, vol. 10, no. 3, pp. 121–130, 2007.
[12] D. P. Kontoyiannis and R. E. Lewis, “Antifungal drug resistance
of pathogenic fungi,” The Lancet, vol. 359, no. 9312, pp. 1135–
1144, 2002.
[13] P. Masˇkovic´, S. Solujic´, V. Mihailovic´ et al., “Phenolic com-
pounds and biological activity of Kitaibelia vitifolia,” Journal of
Medicinal Food, vol. 14, no. 12, pp. 1617–1623, 2011.
[14] E. Grotewold,The Science of Flavonoids, Ohio State University,
Colombus, Ohio, USA, 2006.
[15] T. Arif, J. D. Bhosale, N. Kumar et al., “Natural products—
antifungal agents derived from plants,” Journal of Asian Natural
Products Research, vol. 11, no. 7, pp. 621–638, 2009.
[16] M. Friedman, “Overview of antibacterial, antitoxin, antiviral,
and antifungal activities of tea flavonoids and teas,” Molecular
Nutrition and Food Research, vol. 51, no. 1, pp. 116–134, 2007.
[17] B. O¨zc¸elik, M. Kartal, and I. Orhan, “Cytotoxicity, antiviral and
antimicrobial activities of alkaloids, flavonoids, and phenolic
acids,” Pharmaceutical Biology, vol. 49, no. 4, pp. 396–402, 2011.
[18] M. Zabka and R. Pavela, “Antifungal efficacy of some natural
phenolic compounds against significant pathogenic and toxino-
genic filamentous fungi,” Chemosphere, vol. 93, no. 6, pp. 1051–
1056, 2013.
[19] N. Martins, L. Barros, M. Henriques, S. Silva, and I. C. Ferreira,
“Activity of phenolic compounds from plant origin against
Candida species,” Industrial Crops and Products, vol. 74, pp.
648–670, 2015.
[20] C. Cueva, M. V. Moreno-Arribas, P. J. Mart´ın-A´lvarez et al.,
“Antimicrobial activity of phenolic acids against commensal,
probiotic and pathogenic bacteria,” Research in Microbiology,
vol. 161, no. 5, pp. 372–382, 2010.
[21] A. Scalbert, S. Deprez, I. Mila, A.-M. Albrecht, J.-F. Huneau,
and S. Rabot, “Proanthocyanidins and human health: systemic
effects and local effects in the gut,” BioFactors, vol. 13, no. 1–4,
pp. 115–120, 2000.
[22] M. T. Murray and J. Pizzorno, The Encyclopedia of Natural
Medicine, Atria Books, New York, NY, USA, 2012.
[23] P. A. Balch, Prescription for Nutritional Healing, Penguin Group,
London, UK, 2006.
[24] M.T.Murray and J. Pizzorno,TheEncyclopedia ofHealing Foods,
Simon and Schuster, New York, NY, USA, 2005.
[25] J. D. Sobel, “Vulvovaginal candidosis,”The Lancet, vol. 369, no.
9577, pp. 1961–1971, 2007.
[26] T. J. Lott, R. E. Fundyga, R. J. Kuykendall, and J. Arnold, “The
human commensal yeast, Candida albicans, has an ancient
origin,” Fungal Genetics and Biology, vol. 42, no. 5, pp. 444–451,
2005.
[27] J. Kim and P. Sudbery, “Candida albicans, a major human fungal
pathogen,” Journal of Microbiology, vol. 49, no. 2, pp. 171–177,
2011.
[28] M. Develoux and S. Bretagne, “Candidoses et levuroses
diverses,” EMC Maladies Infectieuses, vol. 2, no. 3, pp. 119–139,
2005.
[29] G. Garc´ıa-Elorriaga and G. Rey-pineda, “Nutrition and intesti-
nal microflora,” Journal of Nutritional Therapeutics, vol. 2, no.
55, pp. 112–121, 2013.
BioMed Research International 13
[30] A. A. Amara and A. Shibl, “Role of Probiotics in health
improvement, infection control and disease treatment and
management,” Saudi Pharmaceutical Journal, vol. 23, no. 2, pp.
107–114, 2013.
[31] J. F. Balch andM. Stengler, Prescription for Natural Cures,Wiley,
Hoboken, NJ, USA, 2004.
[32] J. Balch, M. Stengler, and R. Balch, Prescription for Drug
Alternatives: All-Natural Options for Better Health without the
Side Effects, John Wiley & Sons, New York, NY, USA, 2008.
[33] J. B. Epstein and B. Polsky, “Oropharyngeal candidiasis: a
review of its clinical spectrum and current therapies,” Clinical
Therapeutics, vol. 20, no. 1, pp. 40–57, 1998.
[34] A. T. Sangamwar, U. D. Deshpande, and S. S. Pekamwar,
“Antifungals: need to search for a new molecular target,” Indian
Journal of Pharmaceutical Sciences, vol. 70, no. 4, pp. 423–430,
2008.
[35] A. Lupetti, P. H. Nibbering, M. Campa, M. Del Tacca, and R.
Danesi, “Molecular targeted treatments for fungal infections:
the role of drug combinations,” Trends in Molecular Medicine,
vol. 9, no. 6, pp. 269–276, 2003.
[36] B. M. Alphonsa, P. T. S. Kumar, G. Praveen, R. Biswas, K.
P. Chennazhi, and R. Jayakumar, “Antimicrobial drugs encap-
sulated in fibrin nanoparticles for treating microbial infested
wounds,” Pharmaceutical Research, vol. 31, no. 5, pp. 1338–1351,
2014.
[37] Z. Jiang, J. Gu, C. Wang et al., “Design, synthesis and antifungal
activity of novel triazole derivatives containing substituted 1,2,3-
triazole-piperdine side chains,” European Journal of Medicinal
Chemistry, vol. 82, pp. 490–497, 2014.
[38] E. Lastauskiene, A. Zinkevicˇiene, I. Girkontaite, A. Kaunietis,
and V. Kvedariene, “Formic acid and acetic acid induce a
programmed cell death in pathogenicCandida species,”Current
Microbiology, vol. 69, no. 3, pp. 303–310, 2014.
[39] C. L.Donnici, L. J. Nogueira,M.H.Araujo et al., “In vitro studies
of the activity of dithiocarbamate organoruthenium complexes
against clinically relevant fungal pathogens,” Molecules, vol. 19,
no. 4, pp. 5402–5420, 2014.
[40] S. Wu, Y. Zhang, X. He et al., “From antidiabetic to antifungal:
discovery of highly potent triazole-thiazolidinedione hybrids
as novel antifungal agents,” ChemMedChem, vol. 9, no. 12, pp.
2639–2646, 2014.
[41] N. Martins, L. Barros, C. Santos-Buelga, M. Henriques, S. Silva,
and I. C. F. R. Ferreira, “Evaluation of bioactive properties and
phenolic compounds in different extracts prepared from Salvia
officinalis L.,” Food Chemistry, vol. 170, pp. 378–385, 2015.
[42] S.-S. Wang, D.-M. Wang, W.-J. Pu, and D.-W. Li, “Phyto-
chemical profiles, antioxidant and antimicrobial activities of
three Potentilla species,” BMC Complementary and Alternative
Medicine, vol. 13, article 321, 2013.
[43] W. M. Otang, D. S. Grierson, and R. N. Ndip, “Phytochemical
studies and antioxidant activity of two South African medicinal
plants traditionally used for the management of opportunistic
fungal infections in HIV/AIDS patients,” BMC Complementary
and Alternative Medicine, vol. 12, no. 1, article 43, 2012.
[44] S. Kirbag, F. Zengin, and M. Kursat, “Antimicrobial activities of
extracts of some plants,” Pakistan Journal of Botany, vol. 41, no.
4, pp. 2067–2070, 2009.
[45] M.M. Cowan, “Plant products as antimicrobial agents,”Clinical
Microbiology Reviews, vol. 12, no. 4, pp. 564–582, 1999.
[46] M. Saleem, M. Nazir, M. S. Ali et al., “Antimicrobial natural
products: an update on future antibiotic drug candidates,”
Natural Product Reports, vol. 27, no. 2, pp. 238–254, 2010.
[47] B. B. Petrovska, “Historical review of medicinal plants’ usage,”
Pharmacognosy Reviews, vol. 6, no. 11, pp. 1–5, 2012.
[48] B. Mahesh and S. Satish, “Antimicrobial activity of some
importantmedicinal plant against plant and human pathogens,”
World Journal of Agricultural Sciences, vol. 4, supplement 1, pp.
839–843, 2008.
[49] A.Mathur, R. Singh, S. Yousuf et al., “Antifungal activity of some
plant extracts against clinical pathogens,” Advances in Applied
Science Research, vol. 2, no. 2, pp. 260–264, 2011.
[50] N. C. C. Silva and A. Fernandes Ju´nior, “Biological properties
of medicinal plants: a review of their antimicrobial activity,”
Journal of Venomous Animals and Toxins Including Tropical
Diseases, vol. 16, no. 3, pp. 402–413, 2010.
[51] S. Shi and U. Klotz, “Drug interactions with herbal medicines,”
Clinical Pharmacokinetics, vol. 51, no. 2, pp. 77–104, 2012.
[52] Z. Hu, X. Yang, P. C. L. Ho et al., “Herb-drug interactions: a
literature review,” Drugs, vol. 65, no. 9, pp. 1239–1282, 2005.
[53] B. J. Gurley, E. K. Fifer, and Z. Gardner, “Pharmacokinetic herb-
drug interactions (Part 2): drug interactions involving popular
botanical dietary supplements and their clinical relevance,”
Planta Medica, vol. 78, no. 13, pp. 1490–1514, 2012.
[54] J. Rose, “Herbal and nutritional support for the immune
system,” Clinical Nutrition Insight, vol. 6, no. 2, pp. 1–4, 1999.
[55] M. T.Murray,TheHealing Power of Herbs, RandomHouse, New
York, NY, USA, 2004.
[56] M. S. Greenberg andM.Glick,Burket’s OralMedicine: Diagnosis
and Treatment, BC Decker, New York, NY, USA, 2003.
[57] P. R. Murray, K. S. Rosenthal, and M. A. Pfaller, Medical
Microbiology, 2012.
[58] D. Va´zquez-Gonza´lez, A. M. Perusquı´a-Ortiz, M. Hundeiker,
and A. Bonifaz, “Opportunistic yeast infections: candidiasis,
cryptococcosis, trichosporonosis and geotrichosis,” Journal of
the German Society of Dermatology, vol. 11, no. 5, pp. 381–395,
2013.
[59] L. J. Nohynek, H.-L. Alakomi, M. P. Ka¨hko¨nen et al., “Berry
phenolics: antimicrobial properties and mechanisms of action
against severe human pathogens,”Nutrition and Cancer, vol. 54,
no. 1, pp. 18–32, 2006.
[60] J.-D. Zhang, Z. Xu, Y.-B. Cao et al., “Antifungal activities and
action mechanisms of compounds from Tribulus terrestris L.,”
Journal of Ethnopharmacology, vol. 103, no. 1, pp. 76–84, 2006.
[61] J. Cheel, L. Tu˚mova´, C. Areche et al., “Variations in the
chemical profile and biological activities of licorice (Glycyrrhiza
glabra L.), as influenced by harvest times,” Acta Physiologiae
Plantarum, vol. 35, no. 4, pp. 1337–1349, 2013.
[62] P.Montoro,M.Maldini, M. Russo, S. Postorino, S. Piacente, and
C. Pizza, “Metabolic profiling of roots of liquorice (Glycyrrhiza
glabra) from different geographical areas by ESI/MS/MS and
determination of major metabolites by LC-ESI/MS and LC-
ESI/MS/MS,” Journal of Pharmaceutical and Biomedical Anal-
ysis, vol. 54, no. 3, pp. 535–544, 2011.
[63] N. Trabelsi, P. Waffo-Te´guo, M. Snoussi et al., “Variability of
phenolic composition and biological activities of two Tunisian
halophyte species from contrasted regions,” Acta Physiologiae
Plantarum, vol. 35, no. 3, pp. 749–761, 2013.
[64] M. I. Dias, L. Barros, M. J. Sousa, and I. C. F. R. Ferreira,
“Comparative study of lipophilic and hydrophilic antioxidants
from in vivo and in vitro grown Coriandrum sativum,” Plant
Foods for Human Nutrition, vol. 66, no. 2, pp. 181–186, 2011.
[65] R. F. Martino, R. C. Davicino, M. A. Mattar, Y. A. Casali, S. G.
Correa, and B. Micalizzi, “In vivo effect of three fractions of
14 BioMed Research International
Larrea divaricata Cav. (jarilla) on the innate immune system:
Macrophage response against Candida albicans,” Mycoses, vol.
54, no. 6, pp. e718–e725, 2011.
[66] S. S. Heroor, A. K. Beknal, and N.Mahurkar, “Immunomodula-
tory activity of methanolic extracts of fruits and bark of Ficus
glomerata Roxb. in mice and on human neutrophils,” Indian
Journal of Pharmacology, vol. 45, no. 2, pp. 130–135, 2013.
[67] S. Kumar, G. Sharma, T. Sidiq et al., “Immunomodulatory
potential of a bioactive fraction from the leaves of Phyllostachys
bambusoides (Bamboo) in BALB/C mice,” EXCLI Journal, vol.
13, pp. 137–150, 2014.
[68] E. A. Hayouni, K. Miled, S. Boubaker et al., “Hydroalcoholic
extract based-ointment from Punica granatum L. peels with
enhanced in vivo healing potential on dermal wounds,” Phy-
tomedicine, vol. 18, no. 11, pp. 976–984, 2011.
[69] W.-C. Chen, S.-S. Liou, T.-F. Tzeng, S.-L. Lee, and I.-M. Liu,
“Wound repair and anti-inflammatory potential of Lonicera
japonica in excisionwound-induced rats,”BMCComplementary
and Alternative Medicine, vol. 12, no. 1, article 226, 2012.
[70] M. G. F. Arau´jo, M. Pac´ıfico, W. Vilegas et al., “Evaluation of
Syngonanthus nitens (Bong.) Ruhl. extract as antifungal and in
treatment of vulvovaginal candidiasis,” Medical Mycology, vol.
51, no. 7, pp. 673–682, 2013.
[71] P. Masoko, J. Picard, R. L. Howard, L. J. Mampuru, and J. N.
Eloff, “In vivo antifungal effect of Combretum and Terminalia
species extracts on cutaneous wound healing in immunosup-
pressed rats,” Pharmaceutical Biology, vol. 48, no. 6, pp. 621–632,
2010.
[72] A. Gu¨venc¸, E. K. Akkol, I. Su¨ntar, H. Keles¸, S. Yildiz, and
I. C¸alis¸, “Biological activities of Pseudevernia furfuracea (L.)
Zopf extracts and isolation of the active compounds,” Journal
of Ethnopharmacology, vol. 144, no. 3, pp. 726–734, 2012.
[73] C. Agyare, S. B. Bempah, Y. D. Boakye, P. G. Ayande, M.
Adarkwa-Yiadom, and K. B. Mensah, “Evaluation of antimicro-
bial and wound healing potential of Justicia flava and Lannea
welwitschii,” Evidence-Based Complementary and Alternative
Medicine, vol. 2013, Article ID 632927, 10 pages, 2013.
[74] P. Roy, S. Amdekar, A. Kumar, R. Singh, P. Sharma, and V.
Singh, “In vivo antioxidative property, antimicrobial andwound
healing activity of flower extracts of Pyrostegia venusta (Ker
Gawl) Miers,” Journal of Ethnopharmacology, vol. 140, no. 1, pp.
186–192, 2012.
[75] G. Sahgal, S. Ramanathan, S. Sasidharan,M.N.Mordi, S. Ismail,
and S. M. Mansor, “In vitro and in vivo anticandidal activ-
ity of Swietenia mahogani methanolic seed extract,” Tropical
Biomedicine, vol. 28, no. 1, pp. 132–137, 2011.
[76] S. Vijayarathna, Z. Zakaria, Y. Chen, L. Y. Latha, J. R. Kanwar,
and S. Sasidharan, “The antimicrobial efficacy of elaeis guineen-
sis: characterization, in vitro and in vivo Studies,”Molecules, vol.
17, no. 5, pp. 4860–4877, 2012.
[77] S. L. Jothy, Z. Zakariah, Y. Chen, and S. Sasidharan, “In vitro, in
situ and in vivo studies on the anticandidal activity of Cassia
fistula seed extract,” Molecules, vol. 17, no. 6, pp. 6997–7009,
2012.
[78] J. P. Dzoyem, R. T. Tchuenguem, J. R. Kuiate, G. N. Teke, F. A.
Kechia, and V. Kuete, “In vitro and in vivo antifungal activities
of selected Cameroonian dietary spices,” BMC Complementary
& Alternative Medicine, vol. 14, article 58, 2014.
[79] G. Simonetti, A. R. Santamaria, F. D. D’Auria et al., “Evalua-
tion of anti-Candida activity of Vitis vinifera L. seed extracts
obtained from wine and table cultivars,” BioMed Research
International, vol. 2014, Article ID 127021, 11 pages, 2014.
[80] D. Abaineh and A. Sintayehu, “Treatment trial of subclinical
mastitis with the herb Persicaria senegalense (Polygonaceae),”
Tropical Animal Health and Production, vol. 33, no. 6, pp. 511–
519, 2001.
[81] N. Chelli-Chentouf, A. T. T. Meddah, C. Mullie´, A. Aoues,
and B. Meddah, “In vitro and in vivo antimicrobial activity of
Algerian Hoggar Salvadora persica L. extracts against microbial
strains from children’s oral cavity,” Journal of Ethnopharmacol-
ogy, vol. 144, no. 1, pp. 57–66, 2012.
[82] D. T. Velicˇkovic´, I. T. Karabegovic´, S. S. Stojicˇevic´, M. L. Lazic´, V.
D.Marinkovic´, and V. B. Veljkovic´, “Comparison of antioxidant
and antimicrobial activities of extracts obtained from Salvia
glutinosa L. and Salvia officinalis L.,” Hemijska Industrija, vol.
65, no. 5, pp. 599–605, 2011.
[83] D. S. Bashi, B. S. Fazly Bazzaz, A. Sahebkar, M. M. Karimkhani,
and A. Ahmadi, “Investigation of optimal extraction, antioxi-
dant, and antimicrobial activities ofAchillea biebersteinii andA.
wilhelmsii,” Pharmaceutical Biology, vol. 50, no. 9, pp. 1168–1176,
2012.
[84] A. Parsaeimehr, E. Sargsyan, and K. Javidnia, “A comparative
study of the antibacterial, antifungal and antioxidant activity
and total content of phenolic compounds of cell cultures and
wild plants of three endemic species of Ephedra,”Molecules, vol.
15, no. 3, pp. 1668–1678, 2010.
[85] B. A. Lone, S. A. Bandh, M. Z. Chishti, F. A. Bhat, H. Tak, and
H. Nisa, “Anthelmintic and antimicrobial activity of methanolic
and aqueous extracts of Euphorbia helioscopia L.,” Tropical
Animal Health and Production, vol. 45, no. 3, pp. 743–749, 2013.
[86] D.-D. Li, L.-X. Zhao, E. Mylonakis et al., “In vitro and in vivo
activities of pterostilbene against Candida albicans biofilms,”
Antimicrobial Agents and Chemotherapy, vol. 58, no. 4, pp.
2344–2355, 2014.
[87] Y. Li, Y. Ma, L. Zhang et al., “In vivo inhibitory effect on the
biofilm formation of Candida albicans by liverwort derived
riccardin D,” PLoS ONE, vol. 7, no. 4, Article ID e35543, 2012.
[88] M. Sharma, R. Manoharlal, N. Puri, and R. Prasad, “Antifungal
curcumin induces reactive oxygen species and triggers an early
apoptosis but prevents hyphae development by targeting the
global repressor TUP1 in Candida albicans,” Bioscience Reports,
vol. 30, no. 6, pp. 391–404, 2010.
[89] B. Vanaclocha and S. Can˜igueral, Fitoterapia: Vademecum de
Prescripcio´n, Elsevier Espan˜a, Barcelona, Spain, 2003.
[90] S. Y. Gbedema, K. Emelia, A. Francis, A. Kofi, and W. Eric,
“Wound healing properties and kill kinetics of Clerodendron
splendens G. Don, a Ghanaian wound healing plant,” Pharma-
cognosy Research, vol. 2, no. 2, pp. 63–68, 2010.
Submit your manuscripts at
http://www.hindawi.com
Pain
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Toxins
Journal of
Vaccines
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Antibiotics
International Journal of
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in 
Pharmacological 
Sciences
Tropical Medicine
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Medicinal Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Addiction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Emergency Medicine 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Autoimmune 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anesthesiology 
Research and Practice
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Pharmaceutics
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
